Jason Lang, M.D., M.P.H.
Quick facts
Phase 3 pipeline
- commercially available lansoprazole · Gastroenterology
Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: